$4.2 Billion is the total value of Cormorant Asset Management, LP's 105 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | SPDR S&P 500 ETF TRput | $186,940,000 | +11.6% | 500,000 | 0.0% | 4.45% | -30.9% | |
| BBIO | BRIDGEBIO PHARMA INC | $161,118,000 | +89.5% | 2,265,762 | 0.0% | 3.83% | +17.3% | |
| APLS | APELLIS PHARMACEUTICALS INC | $106,741,000 | +89.6% | 1,866,108 | 0.0% | 2.54% | +17.3% | |
| IWM | ISHARES TRput | $98,030,000 | +30.9% | 500,000 | 0.0% | 2.33% | -19.0% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $75,051,000 | +139.9% | 1,368,550 | 0.0% | 1.79% | +48.5% | |
| AXNX | AXONICS MODULATION TECHNOLOG | $34,595,000 | -2.2% | 693,000 | 0.0% | 0.82% | -39.5% | |
| ZLAB | ZAI LAB LTDadr | $25,592,000 | +62.7% | 189,092 | 0.0% | 0.61% | +0.7% | |
| OMER | OMEROS CORPcall | $14,290,000 | +41.3% | 1,000,000 | 0.0% | 0.34% | -12.6% | |
| ANAB | ANAPTYSBIO INC | $13,975,000 | +45.8% | 650,000 | 0.0% | 0.33% | -9.8% | |
| PLRX | PLIANT THERAPEUTICS INC | $13,891,000 | +2.4% | 611,409 | 0.0% | 0.33% | -36.6% | |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $10,248,000 | +16.5% | 800,000 | 0.0% | 0.24% | -27.8% | |
| HARP | HARPOON THERAPEUTICS INC | $9,478,000 | -2.2% | 570,600 | 0.0% | 0.23% | -39.4% | |
| BCTG | BCTG ACQUISITION CORP | $9,152,000 | +9.4% | 800,000 | 0.0% | 0.22% | -32.3% | |
| RACA | THERAPEUTICS ACQUISITION COR | $6,975,000 | -3.0% | 500,000 | 0.0% | 0.17% | -39.9% | |
| FSDC | FS DEV CORP | $5,500,000 | -1.8% | 500,000 | 0.0% | 0.13% | -39.1% | |
| VSPRU | VESPER HEALTHCARE ACQSTN CORunit 99/99/9999 | $4,848,000 | +18.1% | 400,000 | 0.0% | 0.12% | -27.2% | |
| BCEL | ATRECA INC | $4,740,000 | +15.6% | 293,500 | 0.0% | 0.11% | -28.5% | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $3,774,000 | -23.2% | 422,167 | 0.0% | 0.09% | -52.4% | |
| AVRO | AVROBIO INC | $3,402,000 | +7.1% | 244,032 | 0.0% | 0.08% | -33.6% | |
| PANAU | PANACEA ACQUISITION CORPunit 99/99/9999 | $3,190,000 | +6.3% | 250,000 | 0.0% | 0.08% | -33.9% | |
| DTIL | PRECISION BIOSCIENCES INC | $2,890,000 | +35.4% | 346,524 | 0.0% | 0.07% | -15.9% | |
| ORTX | ORCHARD THERAPEUTICS PLCads | $1,109,000 | +5.1% | 256,649 | 0.0% | 0.03% | -36.6% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| APELLIS PHARMACEUTICALS INC | 26 | Q1 2024 | 8.6% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| ROCKET PHARMACEUTICALS, INC | 25 | Q1 2024 | 2.4% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rapport Therapeutics, Inc. | June 20, 2024 | 1,283,673 | - |
| CytomX Therapeutics, Inc. | May 13, 2024 | 5,750,000 | - |
| TScan Therapeutics, Inc. | April 29, 2024 | 2,500,000 | - |
| Immuneering Corp | April 15, 2024 | 561,128 | - |
| Ventyx Biosciences, Inc. | March 21, 2024 | 3,670,000 | - |
| Corbus Pharmaceuticals Holdings, Inc. | March 18, 2024 | 2,025,000 | - |
| 89bio, Inc.Sold out | February 14, 2024 | 0 | - |
| Aerovate Therapeutics, Inc.Sold out | February 14, 2024 | 0 | - |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 2,550,000 | - |
| Ambrx Biopharma, Inc. | February 14, 2024 | 8,725,040 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-09-24 |
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.